P/E ratio for Neurocrine Biosciences (NBIX)
P/E ratio as of October 2023 (TTM): 61.1
According to Neurocrine Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 61.0874. At the end of 2021 the company had a P/E ratio of 89.7.
P/E ratio history for Neurocrine Biosciences from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 89.7 | 307.81% |
| 2020 | 22.0 | -91.82% |
| 2019 | 269 | -17.21% |
| 2018 | 325 | -781.9% |
| 2017 | -47.6 | 99.26% |
| 2016 | -23.9 | -56.5% |
| 2015 | -54.9 | 101.59% |
| 2014 | -27.2 | 101.27% |
| 2013 | -13.5 | -112.67% |
| 2012 | 107 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 8.88 | -85.46% | 🇺🇸 USA |
 AbbVie ABBV | 30.3 | -50.35% | 🇺🇸 USA |
 Eli Lilly LLY | 75.8 | 24.12% | 🇺🇸 USA |
 Repligen
RGEN | 62.2 | 1.88% | 🇺🇸 USA |
 Athersys ATHX | -0.1389 | -100.23% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | -121 | -298.08% | 🇺🇸 USA |
 Palatin Technologies PTN | -0.5777 | -100.95% | 🇺🇸 USA |
 Royalty Pharma RPRX | 48.7 | -20.20% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.